EUVIMEDEUVIMED entdecken
Open Access

Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis

Bi-Hui Jin, Han Xu, Zi-Yan Zhang, Yu-Hang Fan, Chun-Yan Jiang, Shao-Long Qi, Chen-Yu Xiao, Xiao-Hua Fu, Ling-Bo Qian

International Journal of Molecular Medicine · 08.09.2025 · 56 (5) · 1-14

DOI: 10.3892/ijmm.2025.5630 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 08.09.2025. Verfasst von Bi-Hui Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Han…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Non-alcoholic Fatty Liver Disease, Flavonoids, Sterol Regulatory Element Binding Protein 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with metabolic disturbances, such as non‑alcoholic fatty liver disease (NAFLD), driven by hyperandrogenism‑induced lipogenesis. Baicalin (BA), a flavonoid derived from Scutellaria baicalensis, exhibits therapeutic potential in the treatment of PCOS; however, the specific mechanisms against PCOS‑associated NAFLD remain unclear. In the present study, a PCOS mouse model was established via subcutaneous implantation of dihydrotestosterone. Model validation confirmed irregular estrous cycles, ovarian histopathological abnormalities and altered serum hormone levels. Treatment with BA markedly alleviated NAFLD‑associated metabolic abnormalities, including central obesity, dyslipidemia and hepatic steatosis. Moreover, liver transcriptomics indicated that BA modulated lipid metabolism primarily through sterol regulatory element‑binding protein 1 (SREBP1)‑mediated lipogenesis. Results of western blot analysis confirmed that BA suppressed hepatic protein expression of SREBP1 and its downstream lipogenic enzymes, fatty acid synthase and acetyl‑CoA carboxylase, indicating inhibition of hepatic lipogenesis. As androgen receptor (AR) functions as an upstream transcriptional regulator of SREBP1, network pharmacological analysis highlighted AR as a potential target of BA. Molecular docking predicted the BA‑AR binding site, guiding purification of truncated AR protein for isothermal titration calorimetry (ITC). Subsequently ITC was used to confirm the specific BA‑AR binding affinity. Luciferase reporter assays in MDA‑kb2 cells demonstrated that BA inhibited AR transcriptional activity. Collectively, the results of the present study indicated that BA ameliorates PCOS‑associated NAFLD through targeting the AR/SREBP1 axis, highlighting its potential as a therapeutic strategy for managing lipid metabolism disorders in PCOS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeNon-alcoholic Fatty Liver DiseaseFlavonoidsSterol Regulatory Element Binding Protein 1Receptors, AndrogenAnimalsFemaleMiceHumansLipogenesisDisease Models, AnimalLipid MetabolismMolecular Docking SimulationSignal TransductionLiverMice, Inbred C57BL

Stichwörter der Autor:innen

androgen receptorbaicalinlipid metabolismnon‑alcoholic fatty liver diseasepolycystic ovary syndromesterol regulatory element‑binding protein 1

Substanzen

FlavonoidsSterol Regulatory Element Binding Protein 1baicalinReceptors, AndrogenSrebf1 protein, mouse

Autor:innen und Institutionen

  • Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.
  • Department of Physiology, School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, P.R. China.
  • Department of Reproductive Endocrinology, Center for Reproductive Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 315300, P.R. China.
  • Department of Vascular Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130031, P.R. China.
  • Center for Reproductive Medicine, Department of Gynecology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.

Zitieren

APA

Jin, B. H., Xu, H., Zhang, Z. Y., Fan, Y. H., Jiang, C. Y., Qi, S. L., Xiao, C. Y., Fu, X. H., & Qian, L. B. (2025). Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis. International Journal of Molecular Medicine, 56(5), 1-14. https://doi.org/10.3892/ijmm.2025.5630

Vancouver

Jin BH, Xu H, Zhang ZY, Fan YH, Jiang CY, Qi SL, et al. Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis. International Journal of Molecular Medicine. 2025;56(5):1-14. doi:10.3892/ijmm.2025.5630

BibTeX
@article{Jin2025,
  author = {Jin, Bi-Hui and Xu, Han and Zhang, Zi-Yan and Fan, Yu-Hang and Jiang, Chun-Yan and Qi, Shao-Long and Xiao, Chen-Yu and Fu, Xiao-Hua and Qian, Ling-Bo},
  title = {Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  volume = {56},
  number = {5},
  pages = {1--14},
  doi = {10.3892/ijmm.2025.5630}
}
Kostenlos starten →